120 related articles for article (PubMed ID: 36416415)
21. Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
Chapin JL; Gray LT; Vasilopoulos T; Anderson A; DiBiase L; York JD; Robison R; Wymer J; Plowman EK
PLoS One; 2020; 15(8):e0236804. PubMed ID: 32790801
[TBL] [Abstract][Full Text] [Related]
22. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.
Rooney J; Burke T; Vajda A; Heverin M; Hardiman O
J Neurol Neurosurg Psychiatry; 2017 May; 88(5):381-385. PubMed ID: 27888187
[TBL] [Abstract][Full Text] [Related]
23. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
24. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
25. Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients.
Pinto S; Gromicho M; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):445-448. PubMed ID: 31032642
[No Abstract] [Full Text] [Related]
26. ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale.
Maier A; Boentert M; Reilich P; Witzel S; Petri S; Großkreutz J; Metelmann M; Lingor P; Cordts I; Dorst J; Zeller D; Günther R; Hagenacker T; Grehl T; Spittel S; Schuster J; Ludolph A; Meyer T;
Neurol Res Pract; 2022 Dec; 4(1):60. PubMed ID: 36522775
[TBL] [Abstract][Full Text] [Related]
27. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis.
Franchignoni F; Mora G; Giordano A; Volanti P; Chiò A
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1340-5. PubMed ID: 23516308
[TBL] [Abstract][Full Text] [Related]
28. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
29. Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure.
Abdulla S; Vielhaber S; Körner S; Machts J; Heinze HJ; Dengler R; Petri S
J Neurol; 2013 Sep; 260(9):2242-55. PubMed ID: 23736973
[TBL] [Abstract][Full Text] [Related]
30. Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.
Jackson C; De Carvalho M; Genge A; Heiman-Patterson T; Shefner JM; Wei J; Wolff AA
Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):506-512. PubMed ID: 30379086
[TBL] [Abstract][Full Text] [Related]
31. Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis.
De Marchi F; Berry JD; Chan J; Caldwell S; Ellrodt A; Scalia J; Burke K; Fang T; Clark Sisodia R; Schwamm LH; Moura LMVR; Paganoni S
J Neurol; 2020 Jun; 267(6):1754-1759. PubMed ID: 32125520
[TBL] [Abstract][Full Text] [Related]
32. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
Cedarbaum JM; Stambler N; Malta E; Fuller C; Hilt D; Thurmond B; Nakanishi A
J Neurol Sci; 1999 Oct; 169(1-2):13-21. PubMed ID: 10540002
[TBL] [Abstract][Full Text] [Related]
33. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.
Sanjak M; Langford V; Holsten S; Rozario N; Patterson CGM; Bravver E; Bockenek WL; Brooks BR
Arch Phys Med Rehabil; 2017 Nov; 98(11):2301-2307. PubMed ID: 28465220
[TBL] [Abstract][Full Text] [Related]
34. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
Hu N; Shen D; Yang X; Cui L; Liu M
Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.
Bakker LA; Schröder CD; van Es MA; Westers P; Visser-Meily JMA; van den Berg LH
J Neurol; 2017 Jul; 264(7):1413-1420. PubMed ID: 28608303
[TBL] [Abstract][Full Text] [Related]
36. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials.
Daghlas I; Lever TE; Leary E
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):206-211. PubMed ID: 29260911
[TBL] [Abstract][Full Text] [Related]
37. Modification of the ALSFRS-R for Utilization in Individuals Not Using Noninvasive Ventilation.
Vlok L; Rossouw L; Henning F
Respir Care; 2022 May; 67(5):553-561. PubMed ID: 35473846
[TBL] [Abstract][Full Text] [Related]
38. How common are ALS plateaus and reversals?
Bedlack RS; Vaughan T; Wicks P; Heywood J; Sinani E; Selsov R; Macklin EA; Schoenfeld D; Cudkowicz M; Sherman A
Neurology; 2016 Mar; 86(9):808-12. PubMed ID: 26658909
[TBL] [Abstract][Full Text] [Related]
39. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
[TBL] [Abstract][Full Text] [Related]
40. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.
Hu N; Shen D; Yang X; Cui L; Liu M
J Clin Neurosci; 2022 Mar; 97():93-98. PubMed ID: 35074582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
